Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More

T-Mobile US was upgraded to Buy from Hold by Bank of America with a $220 target, a direct catalyst for near-term positioning.

Likely modest positive drift vs. peers on upgrade/target attention; magnitude depends on how much is already priced.

The article provides a specific rating change and target ($220 vs prior $220 implied by text as new), which is actionable for traders, but it lacks the underlying thesis details.

Gilead Sciences earned a Buy upgrade from HSBC, lifting its target to $155 from $133.

Potential for a positive reaction and relative outperformance around the upgrade window.

Specific upgrade/target numbers are provided, but no new fundamental datapoint (earnings, trial, guidance) is disclosed.

Datadog was downgraded to Market Perform from Outperform at Bernstein, though Bernstein raised its price target to $226 from $180.

Near-term reaction could be muted or two-sided as traders reconcile downgrade vs higher target.

The article includes both rating and target changes, but without the rationale or expected timeframe.

Pfizer was cut to Hold from Buy at HSBC, trimming the target to $28 from $32.

Downside pressure is plausible, especially for traders using analyst-change momentum.

Concrete downgrade and target reduction are provided, but no new company-specific operational or clinical catalyst is included.

Agnico Eagle Mines was upgraded to Buy from Hold at Jefferies, with the price target raised to $200 from $187.

Mild positive bias likely, with reaction size depending on prior positioning.

The article gives the rating/target change but no thesis; also this is a multi-name roundup, which often reduces incremental novelty.

Okta was upgraded to Perform/Outperform from Sector Perform at Scotiabank with a $165 target price.

Potential for a modest positive move around the news cycle.

No additional fundamental detail is provided beyond the rating/target.

Delta Air Lines was cut to Outperform from Strong Buy at Raymond James, with the target raised to $104 from $80.

Reaction could be mixed; traders may focus on the higher target as the more concrete valuation anchor.

The article provides the rating/target numbers but not the rationale or timing of expected catalysts.

JetBlue Airways was downgraded to Underperform from Market Perform at Raymond James, with no price target mentioned.

Potential near-term downside bias, though magnitude is uncertain without a target change.

Only the rating change is specified; absence of target and thesis limits conviction.